Therapeutic Wound Healing Composition of Myricetin-3-O-rhamnoside and Chlorogenic Acid


Reference #: 01295


The University of South Carolina is offering licensing opportunities for a therapeutic wound healing composition of myricetin-3-o-rhamnoside and chlorogenic acid.



The regeneration of healthy and functional skin remains a huge challenge due to its multilayered structure and the presence of different cell types organized within the extracellular matrix. Despite recent advances in wound care products, traditional therapies based on natural compounds, such as plant extracts and natural active components offer viable alternatives, enhancing access to healthcare, and overcoming some limitations associated to the modern products and therapies, such as high costs, long manufacturing times, and increased bacterial resistance.


Invention Description:

This invention is the use of an effective dose of myricetin-3-O-rhamnoside and chlorogenic acid (or their derivatives, analogues, or homologs) to accelerate wound healing. In vitro experiments revealed a cell-specific and dose-dependent response to both compounds. To this end, the effects of the compounds on vascularization and skin wound closure were demonstrated to be promising. Low toxicity compounds with the potential to simultaneously promote vascular formation and skin wound closure is of a high demand. Taken together, these findings show these compounds possess a significant potential for new drug development to treat skin injuries. In addition, they can be used in combination or with current approved treatments in different stages of wound healing process to enhance efficacy in various clinical applications.


Potential Applications:

These compounds can be used separately or in combination with other wound healing agents to promote the wound healing process. It can be applied to different wound problems including ulcers, burns, sunburns, traumatic injuries, hemorrhoids, bedsores, diabetic wounds, and ischemic syndromes such as coronary or peripheral arterial disease and angiogenesis-dependent disease. Moreover, it can be used alone or in combination with other products as a supplement or cosmetic. Specifically, the compounds can be effective when formulated as skin conditioning, UV protective, or antiaging products in the form of a cream, a gel, an ointment, or a skin pad.


Advantages and Benefits:

The use of these compounds can be applied to the treatment of wounds and to the prevention of scars in an array of diseases. Natural bioactive agents most often modulate multiple phases of the healing process, acting through a number of targets by inducing anti-inflammatory, antioxidant, and anti-bacterial effects. Unlike most modalities that only target one aspect of wound healing, myricetin-3-O-rhamnoside and chlorogenic acid simultaneously promotes the wound healing of keratinocytes and fibroblast and enhances vascular tube formation while avoiding many of the side effects associated with current treatments, such as inflammatory responses or the undesired stimulation of other cell types.




Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Compounds for Use in Wound Healing and Angiogenesis Utility United States 16/122,087 11,439,655 9/5/2018 9/13/2022   Notice of Allowance
For Information, Contact:
Technology Commercialization
University of South Carolina
Ehsan Jabbarzadeh
Sara Eslambolchimoghadam
© 2024. All Rights Reserved. Powered by Inteum